Publikationen in Zusammenarbeit mit Forschern von Universidade da Coruña (4)

2020

  1. Palbociclib combined with endocrine therapy in heavily pretreated HR+/HER2- advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP)

    Breast, Vol. 54, pp. 286-292

2019

  1. Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study

    Clinical Breast Cancer, Vol. 19, Núm. 2, pp. 105-112

2017

  1. New clinical trials regulation in Spain: analysis of royal decree 1090/2015

    Clinical and Translational Oncology, Vol. 19, Núm. 3, pp. 291-300

2016

  1. Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study

    Breast Cancer Research and Treatment, Vol. 156, Núm. 1, pp. 81-89